What people reported about GLP-1 drugs

Choose a question to compare what people reported across 8 GLP-1 brands. These FDA reports show what patients and clinicians filed after a drug was used. They do not show how often an effect happens or prove that the drug caused it.

Choose a question

Why has my GLP-1 stopped working?

Measured on 8 of 8Largest report share 6.6%

Drug ineffective is one of the most reported terms for every GLP-1 brand. What the counts show, what they cannot show, and why.

Does a GLP-1 injection hurt?

Measured on 5 of 8Largest report share 11%

Injection-site pain appears more often in FDA reports for some GLP-1 brands than others. See the comparison across eight products.

Does a GLP-1 cause gastroparesis?

Measured on 2 of 8Largest report share 5.2%

What FDA reports say about slow stomach emptying across eight GLP-1 brands. See the counts and why they cannot establish a diagnosis or cause.

How serious are the reports on GLP-1 drugs?

All 8 measuredLargest report share 57%

Compare reports marked serious across eight GLP-1 brands. See the counts, how reporting can differ, and why these shares cannot rank drug safety.

Brands included in the report data

These 8 brands had enough reports for the questions above. We compare brand names instead of adding ingredient totals, which would count the same reports twice.

Each brand, its drug substance, and the FDA reports naming it
Product	Drug substance	Reports naming it
Zepboundsingle-dose pen, single-dose vial, and a multi-dose vial holding four 0.6 mL doses	tirzepatide	70,141 reports
Mounjarosingle-dose pen, single-dose vial, and a multi-dose vial holding four 0.6 mL doses	tirzepatide	93,975 reports
Trulicitysingle-dose pen at 0.75, 1.5, 3 or 4.5 mg — one strength per pen	dulaglutide	88,332 reports
Ozempica 3 mL pen set to one of several doses, holding four doses	semaglutide	66,161 reports
Rybelsusa 3 mg, 7 mg or 14 mg tablet	semaglutide	7,379 reports
Wegovysingle-dose pen or syringe, one strength each; a four-dose pen at 2.4 mg	semaglutide	21,044 reports
Saxendaa 3 mL pen set to 0.6, 1.2, 1.8, 2.4 or 3 mg	liraglutide	10,040 reports
Victozaa pen set to 0.6, 1.2 or 1.8 mg	liraglutide	44,086 reports

401,158 reports in total · read from FDA 2026-08-17 · FDA data last updated 2026-07-30

Why these are not side-effect pages

Our side-effect pages explain the FDA-approved labels. Trial figures count events among enrolled participants over a stated period. That makes them different from a share of submitted reports. You can find those figures in the symptom questions and on each compound guide.

These pages summarize reports filed after a drug was used. The report total is known, but the number of people treated is not available in this data. The figures describe reported events; they cannot estimate how often an event happens or establish its cause.

Use this section to understand a claim based on FDA report counts. Use the label and study pages for the outcomes measured in trials. Neither type of data predicts one person’s experience.

The two limits that shape every page here

The missing number is how many people used each drug. Every percentage here divides an event count by that product’s report total, not by the number of people treated. It is a share of reports, not the chance of an event for a patient.

The snapshot keeps each product’s 25 most-reported terms rather than all of them. A term missing from that list was either never reported or reported outside the stored list. Those rows show upper bounds rather than zero counts. When bounds overlap, the data cannot establish which product has the larger share.

The method is set out in full on the dosing-error study, which is the same snapshot asked the question this section grew out of. How every source on this site is graded is on the sourcing methodology.

Questions this section does not answer

What a dose costs, and whether a plan covers it, is on the cost pages. What a label says about a missed dose or a schedule is on the dose pages. How long a pen keeps outside a fridge is on the storage pages. None of those is a report-stream question, and putting a thin version of them here would only compete with the pages that answer them properly.

Neither does this section answer anything about one person. A share of reports is a fact about a pile of paperwork. Whether something is happening to you, and what to do about it, belongs with a clinician who can see the rest of the picture.